CD19 and acute lymphoblastic leukemia: CD19 CAR T cell therapy is known to induce a high clinical response rate in children and young adults, especially with B-ALL, but relapses are still a current issue [62], explaining, at least in part, the similar OS despite the higher BCR rates found in younger patients.